Effect of rosuvastatin on sortilin and fetuin-A in type 2 diabetic patients: a randomized controlled trial
ConclusionRosuvastatin co-treatment in T2DM patients improves glycemic control and aids in decreasing the atherogenic biomarkers sortilin and fetuin-A levels, so it can be considered tolerable and efficient in improving lipid profile and atherogenic index.Trial registrationClinicalTrials.gov identifier (NCT number): NCT03907423, (The registration date: April 9, 2019).https://clinicaltrials.gov/ct2/show/NCT03907423.
Source: International Journal of Diabetes in Developing Countries - Category: Endocrinology Source Type: research
More News: Cardiology | Cardiovascular | Crestor | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Glimepiride | Heart | HIV AIDS | Insulin | Metformin | Rosuvastatin | Study